Structurally different wheat-derived arabinoxylooligosaccharides have different prebiotic and fermentation properties in rats.

To evaluate the prebiotic potential and intestinal fermentation products of wheat bran-derived arabinoxylooligosaccharides (AXOS) in relation to their structure, 5 preparations with structurally different AXOS were included ( approximately 4% wt:wt) in rat diets that mimicked the average Western human diet composition. Xylooligosaccharides (XOS), fructooligosaccharides (FOS), and inulin were used as references. The observed effects mainly depended on the average degree of polymerization (avDP) of the AXOS preparations. The AXOS and XOS preparations with a low avDP (

Dose-response effect of arabinoxylooligosaccharides on gastrointestinal motility and on colonic bacterial metabolism in healthy volunteers.

OBJECTIVE: Arabinoxylooligosaccharides (AXOS) are non-digestible in the upper gastrointestinal tract and have been shown to exert prebiotic effects in animals. The aim of this study was to characterize the influence of AXOS with an average degree of polymerization of 15 and an average degree of arabinose substitution of 0.26 (AXOS-15-0.26) on gastrointestinal motility and colonic bacterial metabolism in healthy human volunteers. METHODS: Twelve healthy volunteers received five test meals, containing different amounts of AXOS-15-0.26, with one week intervals between each test meal. Breath tests were used to measure gastric emptying rate, oro-cecal transit time (OCTT) and hydrogen excretion. Colonic bacterial metabolism was estimated using the biomarkers lactose-[(15)N, (15)N']-ureide ((15)N-LU) and p-cresol. RESULTS: Gastric emptying and OCTT were not influenced by addition of varying amounts of AXOS-15-0.26. Administration of 2.2g or 4.9 g AXOS-15-0.26 significantly decreased the urinary (15)N-excretion (respectively p = 0.008 and p = 0.035) as compared to the baseline, whereas fecal (15)N-excretion was significantly increased (respectively p = 0.034 and p = 0.019). This shift from urinary to fecal (15)N-excretion suggests a higher uptake or incorporation by bacteria due to the stimulation of colonic bacterial growth and/or metabolic activity. Furthermore, a significant increase in hydrogen excretion after administration of 2.2g (p = 0.002) and 4.9 g (p = 0.004) AXOS-15-0.26 was observed. No influence on urinary p-cresol excretion was observed. CONCLUSION: These findings suggest that a minimal dose of 2.2g AXOS-15-0.26 favorably modulates the colonic bacterial metabolism in healthy humans. However, long term studies are required to confirm a possible prebiotic effect.

Non-digestible oligosaccharides with prebiotic properties.

The search for functional foods or functional food ingredients, i.e. foods or food ingredients that can enhance health, is beyond any doubt one of the leading trends in today's food industry. In this context, probiotics, i.e. living microbial food supplements, and prebiotics, i.e. non-digestible food ingredients, receive much attention. Both popular concepts target the gastrointestinal microbiota. While in the Western world, intake of probiotics has been recommended for long, prebiotics in general, and non-digestible oligosaccharides in particular, have only recently received attention. This review deals with production and characterization of non-digestible oligosaccharides and focuses on their role in promoting health and treating diseases. Attention is paid to the effects of non-digestible oligosaccharides on constipation, mineral absorption, lipid metabolism, cancer prevention, hepatic encephalopathy, glycemia/insulinemia, and immunomodulation.